Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Clinical trial NCT03361852 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03361852
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-14
- Primary completion
- 2026-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.